SwePub - search: WFRF:(Sexton L.)

Enumeration	Reference	Cover	Find
1.	Bravo, L, et al. (author) 2021 swepub:Mat__t
2.	Tabiri, S, et al. (author) 2021 swepub:Mat__t
3.	Aaltonen, T., et al. (author) Combination of Tevatron Searches for the Standard Model Higgs Boson in the W+W- Decay Mode 2010 In: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 104:6, s. 061802- Journal article (peer-reviewed)abstract We combine searches by the CDF and D0 Collaborations for a Higgs boson decaying to W+W-. The data correspond to an integrated total luminosity of 4.8 (CDF) and 5.4 (D0) fb(-1) of p (p) over bar collisions at root s = 1.96 TeV at the Fermilab Tevatron collider. No excess is observed above background expectation, and resulting limits on Higgs boson production exclude a standard model Higgs boson in the mass range 162-166 GeV at the 95% C.L.
4.	Adare, A., et al. (author) Measurements of Elliptic and Triangular Flow in High-Multiplicity He-3 + Au Collisions at root s(NN)=200 GeV 2015 In: Physical Review Letters. - 1079-7114. ; 115:14 Journal article (peer-reviewed)abstract We present the first measurement of elliptic (v(2)) and triangular (v(3)) flow in high-multiplicity He-3 + Au collisions at root s(NN) = 200 GeV. Two-particle correlations, where the particles have a large separation in pseudorapidity, are compared in He-3 + Au and in p + p collisions and indicate that collective effects dominate the second and third Fourier components for the correlations observed in the He-3 + Au system. The collective behavior is quantified in terms of elliptic v(2) and triangular v(3) anisotropy coefficients measured with respect to their corresponding event planes. The v(2) values are comparable to those previously measured in d + Au collisions at the same nucleon-nucleon center-of-mass energy. Comparisons with various theoretical predictions are made, including to models where the hot spots created by the impact of the three He-3 nucleons on the Au nucleus expand hydrodynamically to generate the triangular flow. The agreement of these models with data may indicate the formation of low-viscosity quark-gluon plasma even in these small collision systems.
5.	Adare, A., et al. (author) Measurement of K-S(0) and K(0) in p plus p, d plus Au, and Cu plus Cu collisions at root s(NN)=200 GeV 2014 In:* Physical Review C (Nuclear Physics). - 0556-2813. ; 90:5 Journal article (peer-reviewed)abstract The PHENIX experiment at the Relativistic Heavy Ion Collider has performed a systematic study of K-S(0) and K(0) meson production at midrapidity in p + p, d + Au, and Cu + Cu collisions at root s(NN) = 200 GeV. The K-S(0) and K(0) mesons are reconstructed via their K-S(0) -> pi(0)(-> gamma gamma) pi(0)(-> gamma gamma) and K(0) -> K-+/-pi(-/+) decay modes, respectively. The measured transverse-momentum spectra are used to determine the nuclear modification factor of K-S(0) and K(0) mesons in d + Au and Cu + Cu collisions at different centralities. In the d + Au collisions, the nuclear modification factor of K-S(0) and K(0) mesons is almost constant as a function of transverse momentum and is consistent with unity, showing that cold-nuclear-matter effects do not play a significant role in the measured kinematic range. In Cu + Cu collisions, within the uncertainties no nuclear modification is registered in peripheral collisions. In central collisions, both mesons show suppression relative to the expectations from the p + p yield scaled by the number of binary nucleon-nucleon collisions in the Cu + Cu system. In the p(T) range 2-5 GeV/c, the strange mesons (K-S(0), K(0)) similarly to the phi meson with hidden strangeness, showan intermediate suppression between the more suppressed light quark mesons (pi(0)) and the nonsuppressed baryons (p, (p) over bar). At higher transverse momentum, p(T) > 5 GeV/c, production of all particles is similarly suppressed by a factor of approximate to 2.
6.	Adare, A., et al. (author) Search for dark photons from neutral meson decays in p plus p and d plus Au collisions at root s(NN)=200 GeV 2015 In: Physical Review C (Nuclear Physics). - 0556-2813. ; 91:3 Journal article (peer-reviewed)abstract The standard model (SM) of particle physics is spectacularly successful, yet the measured value of the muon anomalous magnetic moment (g - 2)mu deviates from SM calculations by 3.6 sigma. Several theoretical models attribute this to the existence of a "dark photon," an additional U(1) gauge boson, which is weakly coupled to ordinary photons. The PHENIX experiment at the Relativistic Heavy Ion Collider has searched for a dark photon, U, in pi(0), eta -> gamma e(+)e(-) decays and obtained upper limits of O(2 x 10(-6)) on U-gamma mixing at 90% C.L. for the mass range 30 < m(U) < 90 MeV/c(2). Combined with other experimental limits, the remaining region in the U-gamma mixing parameter space that can explain the (g - 2)(mu) deviation from its SM value is nearly completely excluded at the 90% confidence level, with only a small region of 29 < m(U) < 32 MeV/c(2) remaining.
7.	Figlioli, G, et al. (author) The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer 2019 In: NPJ breast cancer. - : Springer Science and Business Media LLC. - 2374-4677. ; 5, s. 38- Journal article (peer-reviewed)abstract Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658, p.Gln1701, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
8.	Adare, A., et al. (author) Cross section and transverse single-spin asymmetry of eta mesons in p up arrow plus p collisions at root s=200 GeV at forward rapidity 2014 In: Physical Review D (Particles, Fields, Gravitation and Cosmology). - 1550-2368. ; 90:7 Journal article (peer-reviewed)abstract We present a measurement of the cross section and transverse single-spin asymmetry (AN) for. mesons at large pseudorapidity from root s = 200 GeV p up arrow + p collisions. The measured cross section for 0.5 < p(T) < 5.0 GeV/c and 3.0 < vertical bar eta vertical bar < 3.8 is well described by a next-to-leading-order perturbative-quantum-chromodynamics calculation. The asymmetries A(N) have been measured as a function of Feynman-x (x(F)) from 0.2 < vertical bar x(F)vertical bar < 0.7, as well as transverse momentum (p(T)) from 1.0 < p(T) < 4.5 GeV/c. The asymmetry averaged over positive x(F) is < A(N)> = 0.061 +/- 0.014. The results are consistent with prior transverse single-spin measurements of forward eta and pi(0) mesons at various energies in overlapping x(F) ranges. Comparison of different particle species can help to determine the origin of the large observed asymmetries in p up arrow + p collisions.
9.	Adare, A., et al. (author) phi meson production in d plus Au collisions at root s(NN)=200 GeV 2015 In: Physical Review C (Nuclear Physics). - 0556-2813. ; 92:4 Journal article (peer-reviewed)abstract The PHENIX Collaboration has measured phi meson production in d + Au collisions at root s(NN) = 200 GeV using the dimuon and dielectron decay channels. The phi meson is measured in the forward (backward) d-going (Au-going) direction, 1.2 < y < 2.2 (-2.2 < y < -1.2) in the transverse-momentum (pT) range from 1-7 GeV/c and at midrapidity vertical bar y vertical bar < 0.35 in the p(T) range below 7 GeV/c. The phi meson invariant yields and nuclear-modification factors as a function of p(T), rapidity, and centrality are reported. An enhancement of phi meson production is observed in the Au-going direction, while suppression is seen in the d-going direction, and no modification is observed at midrapidity relative to the yield in p + p collisions scaled by the number of binary collisions. Similar behavior was previously observed for inclusive charged hadrons and open heavy flavor, indicating similar cold-nuclear-matter effects.
10.	Adare, A., et al. (author) Systematic study of charged-pion and kaon femtoscopy in Au plus Au collisions at root s(NN)=200 GeV 2015 In: Physical Review C (Nuclear Physics). - 0556-2813. ; 92:3 Journal article (peer-reviewed)abstract We present a systematic study of charged-pion and kaon interferometry in Au + Au collisions at root s(NN) = 200 GeV. The kaon mean source radii are found to be larger than pion radii in the outward and longitudinal directions for the same transverse mass; this difference increases for more central collisions. The azimuthal-angle dependence of the radii was measured with respect to the second-order event plane and similar oscillations of the source radii were found for pions and kaons. Hydrodynamic models qualitatively describe the similar oscillations of the mean source radii for pions and kaons, but they do not fully describe the transverse-mass dependence of the oscillations.
11.	Fachal, L, et al. (author) Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes 2020 In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 52:1, s. 56-73 Journal article (peer-reviewed)
12.	Adare, A., et al. (author) Low-mass vector-meson production at forward rapidity in p plus p collisions at root s=200 GeV 2014 In: Physical Review D (Particles, Fields, Gravitation and Cosmology). - 1550-2368. ; 90:5 Journal article (peer-reviewed)abstract The PHENIX experiment at the Relativistic Heavy Ion Collider has measured low-mass vector-meson ,omega, rho, and phi, production through the dimuon decay channel at forward rapidity (1.2 < vertical bar y vertical bar < 2.2) in p + p collisions at root s = 200 GeV. The differential cross sections for these mesons are measured as a function of both p(T) and rapidity. We also report the integrated differential cross sections over 1 < p(T) < 7 GeV/c and 1.2 < vertical bar y vertical bar < 2.2: d sigma/dy(omega + rho rho -> mu mu) = 80 +/- 6(stat) +/- 12(syst)nb and d sigma/dy(phi -> mu mu) = 27 +/- 3(stat) +/- 4(syst)nb. These results are compared with midrapidity measurements and calculations.
13.	Adare, A., et al. (author) Inclusive cross section and double-helicity asymmetry for pi(0) production at midrapidity in p plus p collisions at root s=510 GeV 2016 In: Physical Review D (Particles, Fields, Gravitation and Cosmology). - 1550-2368. ; 93:1 Journal article (peer-reviewed)abstract PHENIX measurements are presented for the cross section and double-helicity asymmetry (A(LL)) in inclusive pi(0) production at midrapidity from p + p collisions at root s = 510 GeV from data taken in 2012 and 2013 at the Relativistic Heavy Ion Collider. The next-to-leading-order perturbative-quantum-chromodynamics theory calculation is in excellent agreement with the presented cross section results. The calculation utilized parton-to-pion fragmentation functions from the recent DSS14 global analysis, which prefer a smaller gluon-to-pion fragmentation function. The pi(0)A(LL) results follow an increasingly positive asymmetry trend with p(T) and root s with respect to the predictions and are in excellent agreement with the latest global analysis results. This analysis incorporated earlier results on pi(0) and jet A(LL) and suggested a positive contribution of gluon polarization to the spin of the proton Delta G for the gluon momentum fraction range x > 0.05. The data presented here extend to a currently unexplored region, down to x similar to 0.01, and thus provide additional constraints on the value of Delta G.
14.	Mavaddat, N, et al. (author) Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes 2019 In: American journal of human genetics. - : Elsevier BV. - 1537-6605 .- 0002-9297. ; 104:1, s. 21-34 Journal article (peer-reviewed)
15.	Thompson, B.A., et al. (author) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database 2014 In: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 46:2, s. 107-115 Journal article (peer-reviewed)abstract The clinical classification of hereditary sequence variants identified in disease-related genes directly affects clinical management of patients and their relatives. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a collaborative effort to develop, test and apply a standardized classification scheme to constitutional variants in the Lynch syndrome-associated genes MLH1, MSH2, MSH6 and PMS2. Unpublished data submission was encouraged to assist in variant classification and was recognized through microattribution. The scheme was refined by multidisciplinary expert committee review of the clinical and functional data available for variants, applied to 2,360 sequence alterations, and disseminated online. Assessment using validated criteria altered classifications for 66% of 12,006 database entries. Clinical recommendations based on transparent evaluation are now possible for 1,370 variants that were not obviously protein truncating from nomenclature. This large-scale endeavor will facilitate the consistent management of families suspected to have Lynch syndrome and demonstrates the value of multidisciplinary collaboration in the curation and classification of variants in public locus-specific databases. © 2014 Nature America, Inc.
16.	Adare, A., et al. (author) Nuclear matter effects on J/psi production in asymmetric Cu plus Au collisions at root S-NN=200 GeV 2014 In: Physical Review C (Nuclear Physics). - 0556-2813. ; 90:6 Journal article (peer-reviewed)abstract We report on J/psi production from asymmetric Cu + Au heavy-ion collisions at root S-NN = 200 GeV at the Relativistic Heavy Ion Collider at both forward (Cu-going direction) and backward (Au-going direction) rapidities. The nuclear modification of J/psi yields in Cu + Au collisions in the Au-going direction is found to be comparable to that inAu + Au collisions when plotted as a function of the number of participating nucleons. In the Cu-going direction, J/psi production shows a stronger suppression. This difference is comparable in magnitude and has the same sign as the difference expected from shadowing effects due to stronger low-x gluon suppression in the larger Au nucleus.
17.	Polettini, M., et al. (author) Decay studies in the A∼225 Po-Fr region from the DESPEC campaign at GSI in 2021 2022 In: Il Nuovo Cimento. - : Società Italiana di Fisica. - 2037-4909. ; 45:5 Journal article (peer-reviewed)abstract The HISPEC-DESPEC collaboration aims at investigating the structure of exotic nuclei formed in fragmentation reactions with decay spectroscopy measurements, as part of the FAIR Phase-0 campaign at GSI. This paper reports on first results of an experiment performed in spring 2021, with a focus on beta-decaystudies in the Po-Fr nuclei in the 220 < A <230 island of octupole deformation exploiting the DESPEC setup. Ion-beta correlations and fast-timing techniques are being employed, giving an insight into this difficult-to-reach region.
18.	Sawcer, Stephen, et al. (author) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis 2011 In: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 476:7359, s. 214-219 Journal article (peer-reviewed)abstract Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals, and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk. Modestly powered genome-wide association studies (GWAS) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility. Most of the genetic architecture underlying susceptibility to the disease remains to be defined and is anticipated to require the analysis of sample sizes that are beyond the numbers currently available to individual research groups. In a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, we have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci. Within the MHC we have refined the identity of the HLA-DRB1 risk alleles and confirmed that variation in the HLA-A gene underlies the independent protective effect attributable to the class I region. Immunologically relevant genes are significantly overrepresented among those mapping close to the identified loci and particularly implicate T-helper-cell differentiation in the pathogenesis of multiple sclerosis.
19.	Maestre, G, et al. (author) The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs 2023 In: Alzheimer's & dementia : the journal of the Alzheimer's Association. - : Wiley. - 1552-5279. ; 19:3, s. 1105-1108 Journal article (peer-reviewed)
20.	Suarez-Idueta, L, et al. (author) Neonatal mortality risk of large-for-gestational-age and macrosomic live births in 15 countries, including 115.6 million nationwide linked records, 2000-2020 2023 In: BJOG : an international journal of obstetrics and gynaecology. - 1471-0528. Journal article (peer-reviewed)
21.	Kloske, C. M., et al. (author) APOE and immunity: Research highlights 2023 In: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 19:6, s. 2677-2696 Research review (peer-reviewed)abstract INTRODUCTIONAt the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias. METHODSThe meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry. RESULTSDuring the 4-day meeting, presenters illuminated aspects of the cross-talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor alpha [TNF alpha]). DISCUSSIONThis manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
22.	Sexton, Claire E., et al. (author) Novel avenues of tau research 2024 In: Alzheimer's and Dementia. - 1552-5260. ; 20:3, s. 2240-2261 Research review (peer-reviewed)abstract INTRODUCTION: The pace of innovation has accelerated in virtually every area of tau research in just the past few years. METHODS: In February 2022, leading international tau experts convened to share selected highlights of this work during Tau 2022, the second international tau conference co-organized and co-sponsored by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation. RESULTS: Representing academia, industry, and the philanthropic sector, presenters joined more than 1700 registered attendees from 59 countries, spanning six continents, to share recent advances and exciting new directions in tau research. DISCUSSION: The virtual meeting provided an opportunity to foster cross-sector collaboration and partnerships as well as a forum for updating colleagues on research-advancing tools and programs that are steadily moving the field forward.
23.	Antonelli, L, et al. (author) Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer 2023 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 41:34, s. 5296- Journal article (peer-reviewed)
24.	Booth, DR, et al. (author) Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis 2010 In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 42:6, s. 469-470 Journal article (other academic/artistic)
25.	Kalaria, Raj, et al. (author) The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact. 2024 In: Alzheimer's & dementia : the journal of the Alzheimer's Association. - 1552-5279. Journal article (peer-reviewed)abstract Two of every three persons living with dementia reside in low- and middle-income countries (LMICs). The projected increase in global dementia rates is expected to affect LMICs disproportionately. However, the majority of global dementia care costs occur in high-income countries (HICs), with dementia research predominantly focusing on HICs. This imbalance necessitates LMIC-focused research to ensure that characterization of dementia accurately reflects the involvement and specificities of diverse populations. Development of effective preventive, diagnostic, and therapeutic approaches for dementia in LMICs requires targeted, personalized, and harmonized efforts. Our article represents timely discussions at the 2022 Symposium on Dementia and Brain Aging in LMICs that identified the foremost opportunities to advance dementia research, differential diagnosis, use of neuropsychometric tools, awareness, and treatment options. We highlight key topics discussed at the meeting and provide future recommendations to foster a more equitable landscape for dementia prevention, diagnosis, care, policy, and management in LMICs. HIGHLIGHTS: Two-thirds of persons with dementia live in LMICs, yet research and costs are skewed toward HICs. LMICs expect dementia prevalence to more than double, accompanied by socioeconomic disparities. The 2022 Symposium on Dementia in LMICs addressed advances in research, diagnosis, prevention, and policy. The Nairobi Declaration urges global action to enhance dementia outcomes in LMICs.
26.	Lagou, V, et al. (author) GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification 2023 In: Nature genetics. - : Springer Nature. - 1546-1718 .- 1061-4036. ; 55:9, s. 1448- Journal article (peer-reviewed)
27.	Michelsen, B., et al. (author) Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 2020 In: RMD open. - : BMJ. - 2056-5933. ; 6:3 Journal article (peer-reviewed)abstract OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
28.	Sexton, C. E., et al. (author) Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney 2022 In: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 18:1, s. 178-190 Journal article (peer-reviewed)abstract The Alzheimer's Association International Conference held its sixth Satellite Symposium in Sydney, Australia in 2019, highlighting the leadership of Australian researchers in advancing the understanding of and treatment developments for Alzheimer's disease (AD) and other dementias. This leadership includes the Australian Imaging, Biomarker, and Lifestyle Flagship Study of Ageing (AIBL), which has fueled the identification and development of many biomarkers and novel therapeutics. Two multimodal lifestyle intervention studies have been launched in Australia; and Australian researchers have played leadership roles in other global studies in diverse populations. Australian researchers have also played an instrumental role in efforts to understand mechanisms underlying vascular contributions to cognitive impairment and dementia; and through the Women's Healthy Aging Project have elucidated hormonal and other factors that contribute to the increased risk of AD in women. Alleviating the behavioral and psychological symptoms of dementia has also been a strong research and clinical focus in Australia.
29.	Cordtz, R, et al. (author) RISK OF HAEMATOLOGICAL MALIGNANCY IN PATIENTS WITH PSORIATIC ARTHRITIS, OVERALL AND IN RELATION TO TNF INHIBITORS - A NORDIC COHORT STUDY 2022 In: ANNALS OF THE RHEUMATIC DISEASES. - : BMJ. - 0003-4967 .- 1468-2060. ; 81, s. 169-170 Conference paper (other academic/artistic)abstract Several autoimmune inflammatory diseases, including rheumatoid arthritis (RA), are associated with increased risk of malignant lymphomas. There is also a longstanding concern of lymphoma development with tumour necrosis factor inhibitor (TNFi) treatment, but most studies in RA to date do not indicate an additionally increased risk. Corresponding studies in psoriatic arthritis (PsA), both with respect to the underlying risks, and risks in relation to treatment with TNFi, are limited. Data on myeloid malignancies in PsA are scarce.ObjectivesTo estimate the risk of haematological malignancy overall and by lymphoid and myeloid types in TNFi treated versus (vs.) biologics-naïve patients with PsA across the five Nordic countries. Additionally, we investigated the underlying risk of haematological malignancies in PsA as compared to the general population.MethodsWe identified patients with PsA starting a first ever TNFi from the clinical rheumatology registers (CRR) in Sweden (SE), Denmark (DK), Norway (NO), Finland (FI), and Iceland (ICE) from 2006 through 2019 (n=10 621). We identified biologics-naïve patients with PsA from a) the CRR (n=18 705, all countries) and b) the national patient registers (NPR, n=27 286, SE and DK only). To estimate the underlying risk of haematological malignancy in PsA, we randomly sampled general population comparators in SE and DK matched on year of birth, sex, and calendar year at start of follow-up, to the patients with PsA.Through linkage to the mandatory national cancer registers in all five countries, we collected information on haematological malignancy overall, and categorised into lymphoid or myeloid types. By applying a modified Poisson regression, we estimated pooled incidence rate ratio (IRR) with 95% confidence intervals (CI) for TNFi treated vs. biologics-naïve PsA and for PsA vs. the general population, adjusted for age (18-55, 56-65, 66-70, >70 years), sex, calendar period (2006-2010, 2011-2019) and country, and using robust standard errors.ResultsWe observed 40 events of haematological malignancies (during 59 827 person-years) among TNFi treated PsA, resulting in a crude incidence rate (IR) of 67 per 100 000 person-years. The corresponding IR was 91 (63 events) for biologics-naïve PsA from the CRR, and 118 (172 events) for biologics-naïve PsA from NPR. This resulted in a pooled IRR of 0.97 (0.69 to 1.37) for TNFi-treated vs. biologics-naïve PsA patients from the CRR, and 0.84 (0.64 to 1.10) vs. biologics-naïve PsA patients from the NPR. The pooled IRR of haematological malignancies in PsA overall vs. the general population was 1.35 (1.17 to 1.55). Throughout, the estimates were largely similar for lymphoid and myeloid malignancies (Figure 1). The crude IR of haematological malignancies were substantially akin across different TNFi agents.Figure 1.Pooled incidence rate ratios (IRRs) (95% CI) of haematological malignancy overall and by lymphoid and myeloid types, in first ever TNFi treated versus biologics-naïve patients with PsA, and versus general population comparators. Legend: Lymphoid malignancies include international classification of diseases (ICD) 10 codes C81-86, C88, C90-91. Myeloid malignancies include ICD10 codes C92-95, D45-D46, D47.1, D47.3-5. Incidence rate ratios adjusted for age (18-55, 56-65, 66-70, >70 years), sex, calendar period (2006-2010, 2011-2019) and country, and using robust standard errors.ConclusionIn this large five-country cohort study, we did not observe any increased risk of haematological malignancies overall, nor for lymphoid and myeloid types, in patients with PsA treated with TNFi. By contrast, there were signals of a moderately increased underlying risk of haematological malignancies, both of lymphoid and myeloid types, in patients with PsA overall as compared to the general population. The findings are of importance from a patient information perspective.AcknowledgementsWe would like to acknowledge the NordForsk and FOREUM, and especially the patient representatives of the NordForsk collaboration for their valuable contribution to this study.Disclosure of InterestsRené Cordtz: None declared, Johan Askling Consultant of: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Grant/research support from: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Bénédicte Delcoigne: None declared, Karin Ekström Smedby: None declared, Eva Baecklund: None declared, Christine Ballegaard: None declared, Pia Isomäki Speakers bureau: AbbVie, Eli Lilly and Pfizer, Consultant of: AbbVie, Eli Lilly, Pfizer, Roche and ViforPharma, Grant/research support from: Pfizer, Kalle Aaltonen: None declared, Björn Gudbjornsson Speakers bureau: Novartis, not related to this work, Consultant of: Novartis, not related to this work, Thorvardur Love Speakers bureau: Celgene, Sella Aa. Provan: None declared, Brigitte Michelsen Grant/research support from: Novartis, not related to this work, Joe Sexton: None declared, Lene Dreyer Speakers bureau: Eli Lilly, Galderma and Janssen, Grant/research support from: BMS not related to this work, Karin Hellgren: None declared
30.	Draper-Joyce, Christopher J., et al. (author) Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia 2021 In: Nature. - : Springer Nature. - 0028-0836 .- 1476-4687. ; 597:7877, s. 571-576 Journal article (peer-reviewed)abstract The adenosine A(1) receptor (A,R) is a promising therapeutic target for non-opioid analgesic agents to treat neuropathic pain(1,2). However, development of analgesic orthosteric A(1)R agonists has failed because of a lack of sufficient on-target selectivity as well as off-tissue adverse effects(3). Here we show that [2-amino-4-(3,5-bis(trifluoromethyl) phenyl)thiophen-3-yl)(4-chlorophenyl)methanone] (MIPS521), a positive allosteric modulator of the A(1)R, exhibits analgesic efficacy in rats in vivo through modulation of the increased levels of endogenous adenosine that occur in the spinal cord of rats with neuropathic pain. We also report the structure of the co-bound to adenosine, MIPS521 and a G(12) heterotrimer, revealing an extrahelicallipid-detergent-facing allosteric binding pocket that involves transmembrane helixes 1, 6 and 7. Molecular dynamics simulations and ligand kinetic binding experiments support a mechanism whereby MIPS521 stabilizes the adenosine-receptor-G protein complex. This study provides proof of concept for structure-based allosteric drug design of non-opioid analgesic agents that are specific to disease contexts.
31.	Glasø de Lange, Ann-Marie, et al. (author) White matter integrity as a marker for cognitive plasticity in aging 2016 In: Neurobiology of Aging. - : Elsevier BV. - 0197-4580 .- 1558-1497. ; 47, s. 74-82 Journal article (peer-reviewed)abstract Age-related differences in white matter (WM) integrity are substantial, but it is unknown whether between subject variability in WM integrity influences the capacity for cognitive improvement. We investigated the effects of memory training related to active and passive control conditions in older adults and tested whether WM integrity at baseline was predictive of training benefits. We hypothesized that (1) memory improvement would be restricted to the training group, (2) widespread areas would show greater mean diffusivity (MD) and lower fractional anisotropy in older adults relative to young adults, and (3) within these areas, variability in WM microstructure in the older group would be predictive of training gains. The results showed that only the group receiving training improved their memory. Significant age differences in MD and fractional anisotropy were found in widespread areas. Within these areas, voxelwise analyses showed a negative relationship between MD and memory improvement in 3 clusters, indicating that WM integrity could serve as a marker for the ability to adapt in response to cognitive challenges in aging.
32.	Hammer, HB, et al. (author) Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods 2023 In: Scandinavian journal of clinical and laboratory investigation. - 1502-7686. ; 83:5, s. 330-335 Journal article (peer-reviewed)
33.	Hammer, HB, et al. (author) CALPROTECTIN, A SENSITIVE MARKER OF INFLAMMATION, IS ROBUSTLY ASSESSED IN PLASMA FROM PATIENTS WITH ESTABLISHED RA BY USE OF DIFFERENT LABORATORY METHODS 2022 In: ANNALS OF THE RHEUMATIC DISEASES. - : BMJ. - 0003-4967 .- 1468-2060. ; 81, s. 1775-1775 Conference paper (other academic/artistic)abstract Calprotectin (S100A8/S100A9, MRP8/MRP14) in plasma has been shown to be more sensitive than C-Reactive Protein (CRP) or Erythrocyte Sedimentation Rate (ESR) in reflecting inflammatory activity in patients with rheumatoid arthritis (RA).1,2ObjectivesThe present objective was to explore the robustness of laboratory examination of calprotectin by comparing the results from assessments by use of two different methods.MethodsFrozen plasma samples from a study of 177 patients with established RA initiating biologic disease modifying drugs were analysed for calprotectin levels at baseline and after 1, 2, 3, 6 and 12 months by use of either enzyme-linked immunosorbent assay (ELISA) or fluoroenzyme immunoassay (FEIA).The ELISA technique used kits from Calpro AS (Oslo, Norway) and the samples were assessed in a semi-automatic analysis machine Dynex DS2 (Dynex Technologies, Virginia, USA) at Diakonhjemmet hospital. The Calpro AS kits included all necessary buffers, cleansing solutions, enzyme substrate, standards, and controls (high and low calprotectin levels) and their protocol was used for the calprotectin assessments. The standards and controls were used as the mean of two measures, while all the patient samples were analysed as single measures.As a sub-study in NORA (a study exploring personalized medicine in RA by including several study cohorts from the Nordic countries), the same plasma samples were additionally assessed by FEIA. The FEIA technology used the EliATM calprotectin 2 wells in a Research Use Only setting on the PhadiaTM 2500 instrument (Phadia AB, Uppsala, Sweden) with a 1:50 dilution.Spearman was used for correlation assessments. To explore differences across concentration levels the baseline calprotectin levels were divided into 3 groups based on results from the Calpro AS assay (normal levels; ≤ 910 µg/L; moderately elevated; 911-2000 µg/L, highly elevated; > 2000 µg/L).ResultsA total of 917 samples from the 177 patients (mean (SD) age 52.9 (13) years, disease duration 10 years (ranging from a few months to 46 years), 81% women, 78% anti-CCP IgG positive and 81% RF IgM positive) were included. The median of the correlation coefficients between the two methods at the six visits was 0.96 (range 0.91-0.97). Correlations were very high for normal levels (0.91) but somewhat lower for moderate and highly elevated levels (0.85 and 0.79, respectively). There were no significant differences between the associations depending on age, sex, or disease duration, nor on the anti-CCP IgG and RF IgM status of the patient.ConclusionThe present study supports the robustness of calprotectin analyses, showing similar results across two different analytical methods, and that the concentrations were not influenced by demographic or immunological variables. Being a robust and more sensitive marker of inflammation than the commonly used CRP and ESR, calprotectin analyses should be available for assessments of RA patients in routine clinical care.References[1]Hammer, H.B., et al., Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis, 2007. 66(8): p. 1093-7.[2]Hilde Haugedal Nordal HH et al. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis Arthritis Research & Therapy (2017) 19:3Disclosure of InterestsHilde Berner Hammer Speakers bureau: AbbVie, Lilly and Novartis, Sigve Lans Pedersen: None declared, Isabel Gehring: None declared, Linda Mathsson-Alm: None declared, Joe Sexton: None declared, Johan Askling Grant/research support from: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB
34.	Hammer, H, et al. (author) Calprotectin, CRP and ESR as predictive markers of disease activity and remission in patients with early or established rheumatoid arthritis 2023 In: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. - 0300-9742. ; 52, s. 65-67 Conference paper (other academic/artistic)
35.	Hammer, HB, et al. (author) CALPROTECTIN HAS BETTER PREDICTION OF OBJECTIVE ASSESSMENTS OF INFLAMMATION THAN CRP OR ESR; RESULTS FROM TWO NORWEGIAN COHORTS OF EARLY OR ESTABLISHED RA 2023 In: ANNALS OF THE RHEUMATIC DISEASES. - 0003-4967. ; 82, s. 487-487 Conference paper (other academic/artistic)
36.	Jonsson, MK, et al. (author) Anti-Citrullinated Protein Antibody Reactivities in Treatment Naive Early Rheumatoid Arthritis 2017 In: ARTHRITIS & RHEUMATOLOGY. - : BMJ Publishing Group Ltd and European League Against Rheumatism. - 2326-5191. ; 76, s. 522-522 Conference paper (other academic/artistic)
37.	Jonsson, MK, et al. (author) The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy 2018 In: Arthritis research & therapy. - : Springer Science and Business Media LLC. - 1478-6362. ; 20:1, s. 146- Journal article (peer-reviewed)
38.	Khullar, Vik, et al. (author) The relationship between BMI and urinary incontinence subgroups: Results from EpiLUTS. 2014 In: Neurourology and urodynamics. - : Wiley. - 1520-6777 .- 0733-2467. ; 33:4, s. 392-399 Journal article (peer-reviewed)abstract AIMS: To evaluate the relationship between body mass index (BMI) and urinary incontinence (UI) in adults ≥40 from the United States, United Kingdom, and Sweden. METHODS: This was a secondary analysis of EpiLUTS-a population-representative, cross-sectional, Internet-based survey conducted to assess the prevalence and HRQL impact of urinary symptoms. UI was evaluated by the LUTS Tool and categorized by subgroups: no UI, urgency urinary incontinence (UUI), stress urinary incontinence (SUI), mixed urinary incontinence (MUI) (UUI+SUI), UUI+other UI (OI), SUI+OI, and OI. Descriptive statistics were used. Logistic regressions examined the relationship of BMI to UI controlling for demographics and comorbid conditions. RESULTS: Response rate was 59%; 10,070 men and 13,178 women were included. Significant differences in BMI were found across UI subgroups. Obesity rates were highest among those with MUI (men and women), SUI+OI (women), UUI and UUI+OI (men). Logistic regressions of each UI subgroup showed that BMI≥30 (obese) was associated with UI in general and MUI (women) and UUI+OI (men). Among women, being obese increased the odds of having SUI and SUI+OI. Women with BMI 25-29.9 (overweight) were more likely to have UI in general and SUI with and without other incontinence (SUI, MUI, and SUI+OI). Being overweight was unrelated to any form of UI in men. CONCLUSIONS: Results were consistent with prior research showing BMI is associated with higher risk of UI. These findings indicate substantial differences in obesity by gender and UI subtype, suggesting different mechanisms for UI other than purely mechanical stress on the bladder. Neurourol. Urodynam. 9999:1-8, 2013. © 2013 Wiley Periodicals, Inc.
39.	Landström, Hans, 1954-, et al. (author) Remaining Issues and Suggestions for Further Research 2008 In: The Blackwell Handbook of Entrepreneurship. - Oxford : Wiley-Blackwell. - 9780631215738 - 9781405164214 ; , s. 434-443 Book chapter (peer-reviewed)abstract There have been major changes in entrepreneurship, entrepreneurship research, and the importance of entrepreneurship to the economy since the first state-of-the-art in entrepreneurship research book was published in 1982. In response to the changing world economy and research needs, this, the fifth state-of-the-art book and the first international book explores several new areas. In addition, it includes carryover research topics addressed in the earlier volumes that are still in need of additional research to advance our understanding. © Blackwell Publisher Ltd 2000. All rights reserved.
40.	Michelsen, B, et al. (author) 6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network 2019 In: ARTHRITIS & RHEUMATOLOGY. - 2326-5191. ; 71 Conference paper (other academic/artistic)
41.	Ornbjerg, LM, et al. (author) Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? - Real World Data from 12 European Countries in the EuroSpA Research Collaboration 2019 In: ARTHRITIS & RHEUMATOLOGY. - 2326-5191. ; 71 Conference paper (other academic/artistic)
42.	Provan, SA, et al. (author) INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID OR PSORIATIC ARTHRITIS STARTING BDMARDS: INCIDENCE VS. GENERAL POPULATION, AND THE ROLE OF METHOTHREXATE CO-MEDICATION 2023 In: ANNALS OF THE RHEUMATIC DISEASES. - 0003-4967. ; 82, s. 4-5 Conference paper (other academic/artistic)
43.	Sexton, C. C., et al. (author) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS 2009 In: BJU International. - 1464-410X. ; 103:Suppl 3, s. 12-23 Journal article (peer-reviewed)abstract OBJECTIVE: To assess the (i) the overlap between voiding, storage, and postmicturition symptoms; and (ii) the relative effect of bother and implications for treatment seeking within these symptom groups, using data from the EpiLUTS study. SUBJECTS AND METHODS: This cross-sectional population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Participants were asked to rate the frequency and symptom-specific bother of individual LUTS. Descriptive statistics were used to examine differences in International Continence Society LUTS subgroups. Logistc regressions were used with treatment seeking as the dependent variable and the bother of individual symptoms as predictors. RESULTS: The survey response rate was 59%. The sample included 30,000 participants (14,139 men and 15,861 women); 71% of men and 75% of women reported at least one LUTS, and about half reported LUTS from more than one symptom group. Rates of bother were greatest for those who reported multiple storage, voiding and postmicturition LUTS (men 83%, women 89%). Less than a third of participants with LUTS from all three groups reported seeking treatment. Consistent correlates of treatment seeking across genders included bother due to weak stream, incomplete emptying, perceived daytime frequency, nocturia and urgency. There were also significant associations for several types of incontinence, most commonly stress incontinence in women and leaking during sexual activity in men. Despite high rates of symptom overlap and symptom-specific bother, few participants sought treatment for LUTS. CONCLUSION: Common conditions such as BPH and OAB are treatable, and clinicians should proactively ask patients about urinary symptoms. Given the many types of LUTS that patients experience, it is imperative that clinicians assess all LUTS to ensure that appropriate treatments are prescribed.
44.	The Blackwell Handbook of Entrepreneurship 2000 Editorial collection (peer-reviewed)abstract "Overall, the book fills a gaping hole, not only in international entrepreneurship research but also in teaching. This is a perfect text for a graduate course in International Entrepreneurship. For a researcher in this area, the chapters will be a goldmine, providing not only background for research but also provocative research questions. Don Sexton has done it again: bringing together the best minds in entrepreneurship and providing a state of the art look at international entrepreneurship. Excellent job!" Nancy Upton, Baylor University "The book is an interesting collection on international entrepreneurship from a variety of approaches: pure theoretical frameworks, specific applications within selected countries, and cross-country comparisons. The Handbook of Entrepreneurship serves as a course for someone wanting to learn the 'state of the art' of international entrepreneurship." Patricia G Greene, University of Missouri - Kansas City "The Handbook of Entrepreneurship will undoubtedly become one of the most definitive and highly cited works in the field. Sexton and his co-authors have provided the field of entrepreneurship with a reference that identifies and summarizes the contemporary research in the field, anchoring the book with contributions of major scholars. The authors are to be congratulated for stepping out of the North American focus that is typical of most entrepreneurship books indeed, I think many readers will see the more international exploration of this book as one of its key contributions. Overall, [this book} is very well organized, has excellent content, explores interesting issues, and is certain to be found on the bookshelves of most entrepreneurship scholars." Patricia McDougall, Kelley School of Business, Indiana University - Bloomington "This volume is a mix of theoretical and disucssion articles and forms an excellent summary of the research issues int he field to date. As such, it is a volume for the researcher and the academic business library". Business Management. © Blackwell Publisher Ltd 2000. All rights reserved.
45.	Wibetoe, G., et al. (author) Cardiovascular risk age and vascular age estimations in predicting cardiovascular events in rheumatoid arthritis patients 2018 In: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 77, s. 1743-1743 Journal article (other academic/artistic)
46.	Zhang, C, et al. (author) Ion Binding to a Mammalian Sodium/Proton Exchanger Membrane Protein from Molecular Dynamics Simulations 2021 In: BIOPHYSICAL JOURNAL. - 0006-3495. ; 120:3, s. 105A-105A Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Träfflista för sökning "WFRF:(Sexton L.) "

Refine your search

Year